

Raloxifene Versus Standard Hormone Replacement

AMA/CME Test 223

(Test valid through June 30, 2003)

CONTINUING MEDICAL EDUCATION

Goal

To improve clinicians' awareness of the rising incidence of lung cancer in women and the consequent mortality, and to promote more aggressive screening and treatment in this emerging patient population.

Objectives

1. To emphasize the link between the rapid increase in lung cancer among women and the growing number of female smokers, as well as the need for clinicians to take a more active role in encouraging smoking cessation.
2. To explore the capabilities and limitations of current screening modalities for lung cancer, especially computed tomography, and to help identify the appropriate population for screening.
3. To present the latest standard of care for lung cancer therapy based on disease stage and histology.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and Quadrant HealthCom Inc. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

This activity has been peer reviewed and approved by Brian Cohen, MD, professor of clinical OB/GYN, Albert Einstein College of Medicine. Review date: June 2002. It is designed for Primary Care Physicians.

The Albert Einstein College of Medicine designates this educational activity for a maximum of 1 hour in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she spent in the educational activity. Participants who answer 70% or more of the questions correctly will obtain credit.

To earn credit, see the instructions on page 49 and mail your answers according to the instructions on page 50.

DISCLOSURE

The Faculty Disclosure Policy of the College of Medicine requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical or equipment company that might pose a potential, apparent, or real conflict of interest with regard to their contribution to the activity. This disclosure also applies to any discussion of unlabeled or investigational use of any commercial product or device not yet approved in the United States. Dr. Garst reports that she has received grant/research support from Federal R21 and Federal R01 as a co-investigator; serves as a consultant for GlaxoSmithKline; and is on the speaker's bureau/advisory board for Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, and Ortho Biotech. Ms. Campagna and Mr. Coniglio both report no conflict of interest. Dr. Brian Cohen reports no conflict of interest.

Lung Cancer in Women

AMA/CME Test 224

(Test valid through July 31, 2003)

This activity has been planned and produced in accordance with ACCME Essentials. The estimated time to complete this activity is 1 hour.

Instructions: Read the article beginning on page 10 and select the best answer for each of the following questions. Test form and mailing instructions are on the next page.

1. While breast cancer accounts for 15% of all cancer deaths in women, what percentage of female cancer mortality is attributable to lung cancer?
 - a. 10%
 - b. 25%
 - c. 2.5%
 - d. 20%
2. Compared with men, the median survival time for women with small cell lung cancer (SCLC) is:
 - a. up to two times longer.
 - b. about 50% longer.
 - c. about 10% shorter.
 - d. up to five times longer.
3. The most important risk factor for lung cancer in women is:
 - a. smoking during adolescence.
 - b. a history of smoking.
 - c. a family history of lung cancer.
 - d. a family history of chronic pulmonary disease.
4. A smoking-cessation program must address obstacles to quitting, especially:
 - a. anxiety.
 - b. fear of weight gain.
 - c. depression.
 - d. all of the above.
5. Women who smoke can reduce their risk of lung cancer if they:
 - a. use postmenopausal hormone replacement therapy.
 - b. switch to a low-tar brand of cigarettes.
 - c. engage in regular aerobic exercise.
 - d. quit smoking by age 60.
6. Currently, what percentage of lung cancers is diagnosed in the early stages?
 - a. 30%
 - b. 45%
 - c. 15%
 - d. 25%
7. The most promising screening tool for lung cancer is:
 - a. spiral computed tomography (CT).
 - b. radiography.
 - c. sputum cytology.
 - d. positron emission tomography (PET).
8. Younger women with persistent pulmonary symptoms should be evaluated for bronchioloalveolar cancer (BAC), especially if they:
 - a. began smoking in adolescence.
 - b. have never smoked.
 - c. have a history of asthma.
 - d. have a history of cervical atypia or cancer.
9. The current standard of care for limited-stage SCLC is:
 - a. surgery followed by chemotherapy or radiation, depending on the histology.
 - b. targeted radiation.
 - c. surgical resection.
 - d. concurrent chemotherapy and radiotherapy.
10. Overall, the current standard of care for stages I to IIIA non-small cell lung cancer (NSCLC) is:
 - a. neoadjuvant chemotherapy followed by resection.
 - b. concurrent chemotherapy and radiotherapy.
 - c. surgical resection.
 - d. resection followed by a course of intensive radiation.

TheFEMALE PATIENT® / Test 224

Lung Cancer in Women

Lara Campagna, MHS, PA-C; David Coniglio, MPA, PA-C; Jennifer Garst, MD

(Test valid through July 31, 2003. No credit will be given after that date.)

Record your answers here by circling the appropriate letter:

1. a b c d
2. a b c d
3. a b c d
4. a b c d
5. a b c d
6. a b c d
7. a b c d
8. a b c d
9. a b c d
10. a b c d

Name

(Please print)

Last

First

Initial

Degree

Specialty

Address

City

State/ZIP

Phone #

I have read this article and completed this activity in _____ hours.

Signature

Date

For you to obtain credit, 70% or more of your answers must be correct. To cover costs of processing, please enclose a check for \$10, which is tax-deductible, payable to the Division of Continuing Medical Education (TFP), and mail with this answer sheet to:

TFP-CME BOX #2
QUADRANT HEALTHCOM INC.
26 Main St., Chatham, NJ 07928-2402

Participants will receive certification for their records in approximately 10 to 12 weeks.

Course Evaluation

Albert Einstein College of Medicine would like to have your opinion. Your evaluation will help us to plan future CME tests for *The Female Patient*®. We urge you to complete this questionnaire and mail it back to us with your completed test. Thank you for your cooperation.

1. How do you rate the information in this article?
 Superior Satisfactory Unsatisfactory
2. Will the materials presented influence the way you treat your patients?
 Yes No
3. Did this activity meet its objectives?
 Yes No
4. What recommendations do you have to improve this activity?

5. Were any portions of this activity unsatisfactory or inappropriate? If so, which ones?

6. Do you find the information presented in this activity to be fair, objective, and balanced?
 Yes No

7. What subjects would you include in future activities?

8. In your opinion, were the authors biased in their discussion of any commercial product or service?
 Yes No

Comments

